Clinical Trial Update: Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating epirubicin and docetaxel for metastatic breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED